COALITION AGAINST MAJOR DISEASES: DEVELOPMENT OF THERAPEUTIC AREA-SPECIFIC DATA STANDARDS FOR ALZHEIMER’S AND PARKINSON’S DISEASES

Jon Neville1, Steve Kopko2, Bob Stafford3, Andreas Jeromin3, Jerry Novak4, Patricia E. Cole3, Mark Austin5, Klaus Romero1, Joanne Odenkirchen3, Bess LeRoy6, Emily Hartley7, Susan De Santi8, Steve Broadbent7, Enrique Avilés1, Diane Stephenson1

(1) Critical Path Institute (2) Clinical Data Interchange Standards Consortium (3) Atlantic Biomarkers, LLC (4) Janssen R&D (5) Takeda Pharmaceuticals (6) ICOC (7) National Institute for Neurological Disorders and Stroke (8) Piramal Life Sciences

Background and Objectives

Critical Path Institute (C-Path) has played a leadership role in both consensus data standards and precompetitive data sharing for multiple disease areas including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Both of these factors are key to success of clinical trials in the future. Working with the Clinical Data Interchange Standards Consortium (CDISC), C-Path has successfully developed consensus data standards for AD and PD, and a version 2.0 of the AD CDISC standards has been recently completed aimed at biomarkers and early stages of the AD spectrum. These therapeutic area specific standards represent the preferred format by regulatory agencies for submitting new drug applications. Importantly, CDISC standards will be required by FDA for regulatory submission as early as FY 2017. Thus, these standards serve two main purposes: integration of existing data and the prospective collection of clinical trial data.

Methods

A coalition of industry members, regulatory agencies, academic experts, government agencies and patient groups collectively developed data standards in partnership with the Clinical Data Interchange Standards Consortium (CDISC). With input from clinical subject matter experts (SMEs), NINDS (for PD) and ADNI (for AD), working groups of data modelers mapped clinical concepts relevant to AD and PD to the CDISC Study Data Tabulation Model (SDTM) and developed controlled terminology to support the construction of standardized databases for research and regulatory submission in AD and PD.

Results

CDISC therapeutic-area data standards implementation guides were developed for AD and PD in collaboration with CDISC as supplements to the CDISC SDTM, a standard recognized by FDA. The AD user guide represents the first ever therapeutic area CDISC standard developed. The remapping of legacy clinical trial data to the AD standard played a critical role in developing an integrated database of legacy clinical trials, which in turn was a key foundation for the development of the first-ever regulatory-endorsed clinical trial simulation tool. Concepts covered by the AD CDISC user guide include CSF biomarkers, ApoE genotype, volumetric MRI, amyloid PET imaging, and more than 10 clinical outcome assessment scales, including ADAS-Cog, MMSE and CDR. Concepts covered by the PD CDISC user guide include MRI, PET-SPECT, deep brain stimulation, neuropathology, and two clinical outcomes assessments scales: UPDRS and MDS-UPDRS.

Conclusions

The use of consensus data standards maximizes efficiency in regulatory review and facilitates analyses across diverse studies. CDISC standards allow for integrating and pooling data across various stakeholders’ systems in a platform-independent manner. Implementation of CDISC standards, particularly in the biomarkers arena, promises to facilitate improved efficiencies and harmonization in clinical trials.